AdvanDx, Inc. - Medical Equipment - Deals and Alliances Profile

AdvanDx, Inc. - Medical Equipment - Deals and Alliances Profile

Summary

Global Market Direct’s AdvanDx, Inc. - Medical Equipment - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.

AdvanDx (AdvanDx), a privately-held medical device company, is engaged in the development and marketing of molecular-based in vitro diagnostic tests for the diagnosis and prevention of infectious diseases. The company develops PNA FISH and EVIGENE tests that provide rapid identification results for bacteria and yeast to support appropriate antibiotic therapy and improve overall patient care. The company has established Research & Development facilities in United States and Denmark with sales and marketing capabilities located throughout the United States and Europe. The company is headquartered in Massachusetts, the US. Recently, AdvanDx received FDA clearance for PNA FISH Test E. coli/P.

And More inside the report…

Recent Developments

Dec 22, 2009: AdvanDx Receives FDA Clearance For PNA FISH Test
Dec 10, 2009: AdvanDx Receives FDA Clearance For PNA FISH Protocol
Aug 18, 2009: AdvanDx Elects Tina Christensen To Its Board

Scope

- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including mergers & acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

- A quick “one-stop-shop” to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.

Report Highlights

The following companies are the major competitors of AdvanDx, Inc.:

Cepheid Incorporated
Quest Diagnostics Incorporated
Digene Corporation
AccuDx Inc.
[Fade out the market survey infos]

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
AdvanDx, Inc., Medical Equipment, Deals By Year, 2004 to YTD 2010 4
AdvanDx, Inc., Medical Equipment Deals By Type, 2004 to YTD 2010 5
AdvanDx, Inc., Medical Equipment, Deals By Region, 2004 to YTD 2010 6
AdvanDx, Inc., Medical Equipment, Deals By Market, 2004 to YTD 2010 7
AdvanDx, Inc., Medical Equipment, Deals Summary, 2004 to YTD 2010 8
AdvanDx, Inc., Medical Equipment, Deal Details 9
Venture Financing 9
AdvanDx Secures Additional $8 Million In Series C Financing 9
AdvanDx Secures $15 Million Series C Financing 10
AdvanDx Secures $5 Million In Series B-2 Financing 11
Partnerships 12
AdvanDx Enters Into An Agreement With bioMerieux 12
Key Competitors 13
Key Employees 13
Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Recent Developments 15
Corporate Communications 15
Aug 18, 2009: AdvanDx Elects Tina Christensen To Its Board 15
Product News 15
Dec 22, 2009: AdvanDx Announces FDA 510(K) Approval For 90 Minutes PNA FISH Protocol For Identifying Gram-Negative Bloodstream Pathogens 15
Dec 10, 2009: AdvanDx Obtains FDA 510(K) Approval For 90 Minutes PNA FISH Protocol For Identifying Staphylococcal Bloodstream Pathogens 16
Jan 30, 2009: US FDA Grants 510 (k) Clearance To AdvanDx’s E. coli/P. aeruginosa PNA FISH Test 16
Product Approvals 17
Dec 22, 2009: AdvanDx Announces FDA 510(K) Approval For 90 Minutes PNA FISH Protocol For Identifying Gram-Negative Bloodstream Pathogens 17
Dec 22, 2009: AdvanDx Announces FDA 510(K) Approval For 90 Minutes PNA FISH Protocol For Identifying Gram-Negative Bloodstream Pathogens 17
Dec 10, 2009: AdvanDx Obtains FDA 510(K) Approval For 90 Minutes PNA FISH Protocol For Identifying Staphylococcal Bloodstream Pathogens 18
Jan 30, 2009: US FDA Grants 510 (k) Clearance To AdvanDx’s E. coli/P. aeruginosa PNA FISH Test 19
Appendix 20
Methodology 20
About Global Markets Direct 20
Contact Us 20
Disclaimer 20
[Fade out table of contents]

List of Tables
AdvanDx, Inc., Medical Equipment, Key Facts 1
AdvanDx Secures Additional $8 Million In Series C Financing 9
AdvanDx Secures $15 Million Series C Financing 10
AdvanDx Secures $5 Million In Series B-2 Financing 11
AdvanDx Enters Into An Agreement With bioMerieux 12

List of Figures
AdvanDx, Inc., Medical Equipment, Deals By Year, 2004 to YTD 2010 4
AdvanDx, Inc., Medical Equipment, Deals by Type, 2004 to YTD 2010 5
AdvanDx, Inc., Medical Equipment, Deals By Region, 2004 to YTD 2010 6
AdvanDx, Inc., Medical Equipment, Deals by Market, 2004 to YTD 2010 7
[Fade out list of tables / figures]